Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › AstraZeneca, Merck's Lynparza Approved in China for BRCA-Mutated Ovarian Cancer

AstraZeneca, Merck's Lynparza Approved in China for BRCA-Mutated Ovarian Cancer

Dec 05, 2019
|
staff reporter

NEW YORK – AstraZeneca and Merck's olaparib (Lynparza) received approval on Thursday from China's National Medical Products Administration for newly diagnosed advanced ovarian cancer patients whose tumors have somatic or germline BRCA1/2 mutations. 

The drug is intended to be used as a first-line maintenance treatment,which aims to prolong remission and reduce the risk of disease progression in this subset of patients. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
22
Featured Webinar

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

What's Popular?

In Cancer

  1. In Brief This Week: Myriad Genetics, Diaceutics, Agios, Precipio, Lantern Pharma, Guardant Health

  2. MMRF, Dana Farber Amassing Data to Develop Smoldering Multiple Myeloma Monitoring Test

    Premium

  3. Kuur Therapeutics Reports Initial Activity of CAR NK-Cell Therapy in Neuroblastoma

  4. Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit

    Premium

  5. Breast Cancer Risk Gene Associations Refined in Large-Scale Studies

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.